Breaking News

Stylus Medicine Emerges from Stealth

Aims to advance its in vivo genetic medicines platform and pipeline of in vivo therapeutic programs.

Author Image

By: Charlie Sternberg

Associate Editor

Stylus Medicine Inc., a biotechnology company dedicated to developing transformative in vivo genetic medicines, has emerged from stealth with $85 million in financing to advance its in vivo genetic medicines platform and pipeline of in vivo therapeutic programs. The company’s engineering platform combines sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery to enable durable, flexible, and scalable in vivo cell engineering, overcoming major limitations ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters